图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
医药载体系统评论综述
影响因子: 2.9 5年影响因子: 3.72 SJR: 0.573 SNIP: 0.551 CiteScore™: 2.43

ISSN 打印: 0743-4863
ISSN 在线: 2162-660X

医药载体系统评论综述

DOI: 10.1615/CritRevTherDrugCarrierSyst.v17.i2.10
28 pages

Oral Delivery of HIV-Protease Inhibitors

Lilian Y. Li
College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065
Barbra H. Stewart
Parke-Davis/Warner-Lambert, Dept. of Pharmacokinetics, Dynamics, and Metabolism, 2800 Plymouth Rd., Ann Arbor, Michigan 48106-1047
David Fleisher
College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065

ABSTRACT

Strategies for optimizing the oral delivery of HIV-protease inhibitors draw from drug discovery efforts in molecular design, drug development tools in dosage formulation, and dosage regimen considerations in clinical medicine. This review outlines the evolution of these strategies for drugs that have been approved for human use, drug candidates still in development, and molecules that are no longer in development but from which valuable delivery information was obtained. Molecular design for obtaining desirable pharmacokinetics following oral administration primarily involved maximizing aqueous solubility and minimizing first-pass metabolism. Optimization of molecular design for oral drug delivery purposes is tempered by additional considerations for drug potency, toxicity, potential for interactions, and development of viral resistance. Strategies for improving oral bioavailability dirough dosage formulation use information from the effects of coadministered meals on drug plasma levels. Patient adherence to dosage regimens remains a major issue in assuring effective oral drug treatment and in preventing the development of resistance. Progress has been made in clinical studies where improved oral bioavailability and reductions in drug plasma level variability have been achieved with appropriate dosage regimen adjustment.


Articles with similar content:

Oral Insulin: Current Status, Challenges, and Future Perspectives
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 4
Gaurav Gupta, Yap Yenese, Jestin Chellian, Chew Chian Wei, Dinesh Kumar Chellappan
Long-Acting Injectables: Current Perspectives and Future Promise
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 2
Komal Chaudhary, Mayur M. Patel, Priti J. Mehta
Current Nanotechnological Strategies for Effective Delivery of Bioactive Drug Molecules in the Treatment of Tuberculosis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 1
Mandeep Kaur, Goutam Rath, Tarun Garg, Amit Kumar Goyal
Oral Absorption Promoters: Opportunities, Issues, and Challenges
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 5
Sushilkumar Patil, Girish Kore, Atul Kolate, Chetan Yewale, Ambikanandan Misra
Structuring Polymers for Delivery of DNA-Based Therapeutics: Updated Insights
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 6
Suresh P. Vyas, Shailja Tiwari, Madhu Gupta